Home/Filings/4/0000950170-25-051658
4//SEC Filing

Paulson Richard A. 4

Accession 0000950170-25-051658

CIK 0001503802other

Filed

Apr 6, 8:00 PM ET

Accepted

Apr 7, 4:59 PM ET

Size

5.3 KB

Accession

0000950170-25-051658

Insider Transaction Report

Form 4
Period: 2025-04-04
Paulson Richard A.
DirectorPresident and CEO
Transactions
  • Sale

    Common Stock

    2025-04-04$3.74/sh245$91682,739 total
Footnotes (2)
  • [F1]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on June 10, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
  • [F2]Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $3.74 to $3.86, inclusive. The reporting person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Documents

1 file

Issuer

Karyopharm Therapeutics Inc.

CIK 0001503802

Entity typeother

Related Parties

1
  • filerCIK 0001804460

Filing Metadata

Form type
4
Filed
Apr 6, 8:00 PM ET
Accepted
Apr 7, 4:59 PM ET
Size
5.3 KB